Monopar Therapeutics Inc (MNPR) returns
Monopar Therapeutics returns over 5 years
$1,000 invested in Monopar Therapeutics five years ago was worth $2,930 at the close on October 30, 2026, with dividends reinvested: an average return of 24.0% a year. The same $1,000 in the S&P 500 (SPY) became $1,760.
Total return by period
| Period | Total return | A year, on average | $1,000 became | S&P 500 (SPY) |
|---|---|---|---|---|
| 1 month | -11.7% | — | $882.64 | -0.9% |
| 3 months | -38.7% | — | $613.29 | +2.1% |
| Year to date | +7.7% | — | $1,077 | +11.7% |
| 1 year | -17.9% | — | $820.82 | +12.4% |
| 3 years | +3,381% | +226.5% | $34,812 | +88.5% |
| 5 years | +193.0% | +24.0% | $2,930 | +76.0% |
Monopar Therapeutics return by calendar year
| Year | MNPR | S&P 500 (SPY) | Difference |
|---|---|---|---|
| 2026 to date | +7.7% | +11.7% | -4.0% |
| 2025 | +196.8% | +17.7% | +179.1% |
| 2024 | +1,193% | +24.9% | +1,168% |
| 2023 | -85.6% | +26.2% | -111.8% |
| 2022 | -26.2% | -18.2% | -8.0% |
| 2021 | -47.5% | +28.7% | -76.3% |
| 2020 | -63.1% | +18.4% | -81.5% |
Past returns do not predict future returns. Returns are computed from our daily closes, adjusted for splits and with dividends reinvested on their ex-dates; taxes and trading costs are left out.
See also:
No forecast, no recommendation. This page describes Monopar Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.